Back to Browse Journals » Breast Cancer: Targets and Therapy » Volume 4

Role of pertuzumab in the treatment of HER2-positive breast cancer

Authors Hubalek M, Brantner C, Marth C

Published Date May 2012 Volume 2012:4 Pages 65—73

DOI http://dx.doi.org/10.2147/BCTT.S23560

Received 1 March 2012, Accepted 13 March 2012, Published 28 May 2012

Michael Hubalek, Christine Brantner, Christian Marth
Brustgesundheitzentrum Tirol, Department of Obstetrics and Gynecology, Innsbruck Medical University, Innsbruck, Austria

Abstract: Pertuzumab, a humanized monoclonal antibody to the HER2 receptor, represents a promising new anti-HER2 agent with a novel mechanism of action targeting the inhibition of HER2 dimerization. Nonclinical and clinical data to date indicate that pertuzumab provides a broader HER2 blockade through the inhibition of HER2 heterodimerization. In preclinical experiments, pertuzumab has demonstrated superior antitumor effects when combined with other anti-HER2 treatments such as trastuzumab, compared to when used as monotherapy. Trastuzumab and pertuzumab monoclonal antibodies bind to distinct epitopes on the HER2 receptor without competing with each other, resulting in distinctive mechanisms for disrupting HER2 signaling. These mechanisms are complementary and result in augmented therapeutic efficacy when pertuzumab and trastuzumab are given in combination. Clinically, pertuzumab may have optimal therapeutic effects when given to patients with HER2-positive cancers, in combination with trastuzumab. This observation is supported by recent clinical trials in the metastatic as well as neoadjuvant setting. Intravenous pertuzumab had an acceptable tolerability profile when added to trastuzumab and chemotherapy. This overview will review recent advances in the clinical development of this HER2-targeted therapy.

Keywords: HER2, breast cancer, pertuzumab, trastuzumab

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors

Eduardo Pimenta, Suzanne Oparil

Vascular Health and Risk Management 2009, 5:453-463

Published Date: 19 May 2009

New developments in the treatment of HER2-positive breast cancer

Nahta R

Breast Cancer: Targets and Therapy 2012, 4:53-64

Published Date: 7 May 2012

Potential of afatinib in the treatment of patients with HER2-positive breast cancer

Geuna E, Montemurro F, Aglietta M, Valabrega G

Breast Cancer: Targets and Therapy 2012, 4:131-137

Published Date: 27 August 2012

Current and emerging quantitative magnetic resonance imaging methods for assessing and predicting the response of breast cancer to neoadjuvant therapy

Abramson RG, Arlinghaus LR, Weis JA, Li X, Dula AN, Chekmenev EY, Smith SA, Miga MI, Abramson VG, Yankeelov TE

Breast Cancer: Targets and Therapy 2012, 4:139-154

Published Date: 11 October 2012

Therapeutic reduction mammoplasty in large-breasted women with cancer using superior and superomedial pedicles

Denewer A, Shahatto F, Elnahas W, Farouk O, Roshdy S, Khater A, Hussein O, Teima S, Hafez M, Zidan S, Shams N, Kotb S

Breast Cancer: Targets and Therapy 2012, 4:167-172

Published Date: 25 October 2012

Dormancy in breast cancer

Banys M, Hartkopf AD, Krawczyk N, Kaiser T, Meier-Stiegen F, Fehm T, Neubauer H

Breast Cancer: Targets and Therapy 2012, 4:183-191

Published Date: 5 December 2012